Massive sympathetic nerve infiltration in advanced hepatic alveolar echinococcosis: a case report and review of the literature

Zongding Wang1,2†, Tiemin Jiang1,2†, Tuerganaili Aji1,2 and Hao Wen1,2*

Abstract
Background: Alveolar echinococcosis is a zoonotic disease that mostly affects the liver, with vascular invasion and a protean clinical symptom. However, no reports of sympathetic nerve infiltration in hepatic alveolar echinococcosis have been reported. Here, we report a case of hepatic alveolar echinococcosis in a 33-year-old man. In this end-stage case, the lesion was heavily involved in the large vessels and biliary tract, and immunohistochemistry also incidentally revealed extensive nerve infiltration in the specimens after surgical treatment. Subsequently, neural classification was identified.

Case presentation: We herein report a case of advanced hepatic alveolar echinococcosis with macrovascular invasion and sympathetic nerve infiltration. In this case, inferior vena cava (IVC), the portal vein and bile duct were infiltrated. Ultimately, according to our experience, ex vivo liver resection and autotransplantation (ELRA) was the optimal treatment way to perform for this resectable patient. Samples were collected from normal liver tissue, junction tissue and the lesion. Hematoxylin–eosin (HE) staining was used to confirm the diagnosis. Neural infiltration was observed by immunohistochemical staining with protein gene product 9.5 (PGP9.5). Fluorescence colocalization was determined with PGP9.5 and tyrosine hydroxylase (TH). These results suggest that a large amount of sympathetic nerve infiltration occurred at the junction.

Conclusion: This study suggests that advanced hepatic alveolar echinococcosis shows infiltrating growth, often invades the large vessels and biliary ducts, and may be accompanied by sympathetic nerve infiltration.

Keywords: Alveolar echinococcosis, Sympathetic nerve, Neural infiltration, Liver transplantation, Case report

Background
Echinococcosis, a zoonotic disease caused by cestodes of the genus Echinococcus (family Taeniidae), remains a major public health issue. Alveolar echinococcosis (AE) is mainly caused by infection and prevalent in humans and animals. Its main pathological feature is the presence of metacestode (larva) of E. multilocularis in the internal organs, which destroy normal organ tissue and result in alveolar echinococcosis. The most targeted organ for echinococcosis is the liver (95%) [1]. In fact, exceptionally, some primary extra-hepatic AE localizations may be observed. It results in a mortality rate of 90% after 10 to 15 years if untreated [2]. We report a case of progressive hepatic alveolar echinococcosis who had tumor-like nodule formation and massive sympathetic nerve infiltration.

†Zongding Wang and Tiemin Jiang contributed equally to this work
*Correspondence: Dr.wenhao@163.com
1 State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, NO.137 Li Yu Mountain South Road, Ürümqi 830054, Xinjiang, People's Republic of China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Case presentation**

The patient was a 33-years-old male who was a herder living in Tibetan Plateau. He denied any history of smoking, alcohol, food allergy and drugs, and had no evident past medical history or history evident in family members. He was admitted to our hospital because of intermittent jaundice and scleral icterus. Also, he complained of bloating and an occasional bout of diarrhea. The patient did not receive any medications prior to admission. Physical examination revealed an epigastric mass and mild pitting edema in both lower limbs.

Laboratory investigation showed that hemoglobin was 93.0 g/dL, the white blood count was $5.85 \times 10^9$/L, the platelet count was $184.0 \times 10^9$/L, the international normalized ratio was 1.17, glucose was 4.15 mmol/L, and blood urea nitrogen was 3.28 mmol/L. Liver function tests showed the bilirubin total/direct was 285.70/136.31 µmol/L. Aspartate aminotransferase was 75.70 U/L, alanine aminotransferase was 44.45 U/L, and gamma glutamyl transferase was 79.47 U/L. Alpha-fetoprotein (AFP) was 1.99 ng/mL, CA 125 (cancer antigen 125) was 153.50, and carcinoembryonic antigen (CEA) was 1.69 ng/mL. Contrast-enhanced abdominal CT showed a 19.32 cm × 13.85 cm mass in the right hepatic lobe, encroaching the second hepatic hilum and compressing the inferior vena cava (IVC), and a large number of calcifications were observed. The right portal vein, middle and right hepatic veins and bile duct were all involved. Signs of portal hypertension, such as cavernous transformation of the portal vein (CTPV), ascites, and splenomegaly, were observed (Fig. 1A, B).

Due to the low sensitivity and specificity of AE molecular diagnosis, we did not adopt it. On the basis of the long-life history of epidemic area, abdominal CT scan

![Fig. 1](image-url)
findings and laboratory examinations, a presumptive diagnosis of AE with Budd–Chiari syndrome (BCS) was made. The patient’s staging score was P3N0M0 (stage III a) based on parasitic liver mass, adjacent organ involvement, and metastasis (PNM) [3]. Preoperative biliary drainage was performed by endoscopic retrograde cholangiopancreatography (ERCP). The jaundice quickly declined after 3 weeks. Subsequently, emergency endoscopic hemostasis was conducted for upper gastrointestinal bleeding due to portal hypertension. The patient underwent ex vivo liver resection and auto transplantation (ELRA) after the extrahepatic lesions were resected. Samples were taken from the liver lesion, normal tissue, and the junction between each other (Fig. 1C). All liver tissues were fixed for more than 24 h, and then cut into 5 µm sections after paraffin embedding. Hematoxylin–eosin (HE) staining and immunohistochemical staining were performed according to the instructions [4]. HE staining showed abundant granulomatous reaction and coagulative necrosis around the laminated parasitic membranes (Fig. 1D–F). A large number of nerves were observed at the junction by immunohistochemistry (Fig. 1G–I), and these were identified as sympathetic nerves by fluorescence colocalization (Fig. 2). Follow-up 3 months after treatment showed complete relief of the symptoms.

**Discussion and conclusion**

AE is a regionally endemic disease [5]. The fecal–oral route is the main mode of transmission of AE. After adult *echinococcus multilocularis* mature in the intestinal tract of the definitive host, it produces a large number of eggs which are released into the environment through the feces of carnivores. Humans are usually indirectly involved in *E. multilocularis* eggs transmission as intermediate hosts. The eggs hatch in the human intestine after being ingested by humans in the contaminated environment, a small amount larvae pass through the intestinal wall into lymphatic vessels or portal vein. It usually settles in the liver and develops as larvae [1]. They also travel through the bloodstream to other organs, including the brain [6, 7], lungs [8, 9], and bone tissue [10, 11].

Liver is the main target organ of *E. multilocularis*. The pathological morphological characteristics are mainly shown as vesicle aggregation, with different sizes. The gross anatomy is often characterized by a large or single nodular, yellowish or white cystic mass with a hard texture. The growth of AE is characterized by strong invasiveness and unclear boundary with surrounding organs and tissues. Lymphatic or vascular invasion provides an opportunity for distant metastasis [12]. The most common site of extrahepatic metastases of AE patients is the lung, followed by brain, bone, and kidney, while heart and other organs are rarely involved. The early stage of AE is asymptomatic and usually lasts 10 to 15 years, which results in losing the best opportunity for early diagnosis and treatment [10].

In terms of treatment, radical surgery often needs to be combined with albendazole medication to achieve the purpose of radical treatment, which is considered as the major treatment for clinically diagnosed AE patients. Surgical procedures include radical hepatectomy, ELRA, classical allogeneic liver transplantation, and palliative treatment (partial resection of the lesion, centro-parasitic abscess or biliary drainages, surgical biliary derivations). Liver transplantation is the main indication for patients with end-stage hepatic alveolar echinococcosis [13–16]. The major advantages of ELRA in patients with advanced AE over classical allogeneic liver transplantation include the absence of organ donors [1, 17] and postoperative immunosuppressive therapy [18, 19]. Therefore, in this case, we reported a patient who lost the opportunity for conventional surgical procedures and underwent ELRA.

The liver is one of the most highly innervated organs in mammals. Autonomic innervation includes vagus and sympathetic fibers, which coordinate with each other to achieve the balance of normal functions. Hepatic nerves are involved in the regulation of various physiological functions, such as carbohydrate metabolism, glucose regulation, lipid metabolism, food intake, and biliary

**Fig. 2** Hepatic sympathetic nerves were identified by confocal laser scanning microscopy. The results of PGP9.5/Tyrosine hydroxylase (TH) colocalization staining showed that hyperplastic sympathetic nerves in junctional tissue. The arrowhead showed the sympathetic nerves. (Scale bar: 75 µm)
secretion [20]. To date, only one case of hepatic AE has been reported with nerve infiltration, however, the types of nerves remain unclear [21]. Our study addressed this question, we described the location of the nerves, which was identified as sympathetic nerve.

In addition, there is an overwhelming body of evidence that the sympathetic system participates in the so-called “fight and flight response” [22], which is believed to be associated with the inflammatory response [23]. Some studies also confirmed that the sympathetic nervous system promotes hepatocarcinogenesis [24]. Furthermore, the sympathetic nerve is also involved in the metastatic process observed in malignant lesions [25]. Similarly, massive inflammatory cell infiltration in junctional tissue was observed by histopathological staining, which is consistent with the location of sympathetic infiltration. Whether sympathetic nerves are involved in inflammatory reactions in AE needs to be verified by more patient samples. Moreover, the pathological features of AE are similar to those of cancer, and whether the sympathetic nerve plays the same role in AE also needs to be confirmed by further experiments.

In conclusion, this case demonstrates aggressive growth in patients with advanced hepatic alveolar echinococcosis. There is a large amount of sympathetic infiltration in liver tissue around the lesion, which may be involved in immune regulation.

**Abbreviations**
AE: Alveolar echinococcosis; IVC: Inferior vena cava; BCS: Budd–Chiari syndrome; ELRA: Ex vivo liver resection and auto transplantation; HE: Hematoxylin–eosin; TH: Tyrosine hydroxylase; PGP9.5: Protein gene product 9.5; cavernous CTPV: Transformation of the portal vein; ERCP: Endoscopic retrograde cholangiopancreatography.

**Acknowledgements**
The authors thank Mustapa-Zayer for imaging data collection and analysis.

**Author contributions**
ZW and TJ wrote treated the patient and collected clinical data; this manuscript was initially drafted by ZW, TJ. Then revised by AJ and HW. All authors read and approved the final manuscript.

**Funding**
This study was supported by the Project of Introducing Talents to New Disciplines in Local Colleges and Universities (111 Project, D17010) and the Xinjiang Key Laboratory of Open Topic (2021D00402). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**
The datasets generated and/or analyzed during the current study are available in the [jianguoyun] repository, [https://www.jianguoyun.com/p/DdwAc78QtJiDChz7poE].

**Declarations**

**Ethics approval and consent to participate**
This case report has been approved by Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (K202109-14).

**Consent for publication**
Written informed consent was obtained from the patient for publication of information and images in this case-report. A copy of the written consent is available for review by the editor of this journal.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1 State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, NO.137 Li Yu Mountain South Road, Ürümqi 830054, Xinjiang, People’s Republic of China. 2 Hepatobiliary and Hydatid Disease Department, First Affiliated Hospital of Xinjiang Medical University, NO.137 Li Yu Mountain South Road, Ürümqi 830054, Xinjiang, People’s Republic of China.

Received: 15 November 2021 Accepted: 17 May 2022 Published online: 23 May 2022

**References**

1. Wen H, Vutilton L, Tuxun T, Li J, Vutilton DA, Zhang W, et al. Echinococcosis: advances in the 21st century. Clin Microbiol Rev. 2019;32(2):e00075–18.
2. Bułaki E, Kartal MG, Yilmaz S, Yilmaz E, Yilmaz R, Sahin Ö, et al. Multimodality imaging in diagnosis and management of alveolar echinococcosis: an update. Diagn Interv Radiol. 2016;22(3):247–56.
3. Kern P, Wen H, Sato N, Vutilton DA, Gruener B, Shao Y, et al. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2006;55(Suppl):S283–7.
4. Hu Y, Lou J, Mao YY, Lai TW, Liu HY, Zhu C, et al. Activation of M1R in pulmonary epithelium promotes LPS-induced acute lung injury. Autophagy. 2016;12(12):2286–99.
5. Craig PS, Hegglin D, Lightowers MW, Torgerson PR, Wang Q. Echinococcosis: control and prevention. Adv Parasitol. 2017;96:155–158.
6. Tappe D, Weise D, Ziegler U, Muller A, Mullges W, Stich A. Brain and lung metastasis of alveolar echinococcosis in a refugee from a hyperendemic area. J Med Microbiol. 2008;57(Pt 11):1420–3.
7. Turgut AT, Turgut M. Fatal liver and lung alveolar echinococcosis with newly developed neurologic symptoms due to the brain involvement. Surg J. 2017;3(2):e90.
8. Aydin Y, Oglu H, Topdagi O, Ulas AB, Sade R, Ozturk G, et al. Relevance of pulmonary alveolar echinococcosis. Arch Bronconeumol. 2020;56(12):779–83.
9. Wang H, Lu C, Liu X, Zhang W. Metastatic and prognostic factors in patients with alveolar echinococcosis. Int J Clin Exp Pathol. 2015;8(9):11192–8.
10. Fieder B, Larrieu E, Odriozola M. Long-term outcome of asymptomatic liver hydatidosis. J Hepatol. 1999;30(2):228–31.
11. Barth TFE, Gasulli A. Morphological characteristics of alveolar and cystic echinococcosis lesions in human liver and bone. Pathogens. 2021;10(10):1326.
12. Demir MK, Kilicoglu G, Akinci O. Alveolar hydatid disease of the liver: brief review and spectrum of adjacent organ invasion. Australas Radiol. 2007;51(4):546–50.
13. Wen H, Dong JH, Zhang JH, Zhao JM, Shao YM, Duan WD, et al. Ex vivo liver resection followed by autotransplantation for end-stage hepatic alveolar echinococcosis. Chin Med J. 2011;124(18):2813–7.
14. Aji T, Dong JH, Shao YM, Zhao JM, Li T, Tuxun T, et al. Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis. J Hepatol. 2018;69(5):1037–46.
15. Beldi G, Vutilton D, Lachenmayer A, Heyd B, Duflot JF, Richou C, et al. Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe? J Hepatol. 2019;70(5):1030–1.
16. Shen S, Kong J, Qui Y, Zhang S, Qin Y, Wang W. Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis. Int J Infect Dis. 2019;79:87–93.
17. Zhang Y, Xie P, Yang C, Yang H, Liu J, Zhou G, et al. Percutaneous stenting of left hepatic vein followed by ex vivo liver resection and
autotransplantation in a patient with hepatic alveolar echinococcosis with Budd–Chiari syndrome. Int J Surg Case Rep. 2020;68:251–6.

18. Vuitton DA, Azizi A, Richou C, Vuitton L, Blagosklonov O, Delabrousse E, et al. Current interventional strategy for the treatment of hepatic alveolar echinococcosis. Expert Rev Anti Infect Ther. 2016;14(12):1179–94.

19. Hillenbrand A, Grueber B, Kratzer W, Kern P, Graeter T, Barth TF, et al. Impact of safe distance on long-term outcome after surgical therapy of alveolar echinococcosis. World J Surg. 2017;41(4):1012–8.

20. Miller BM, Oderberg IM, Goessling W. Hepatic nervous system in development, regeneration, and disease. Hepatology. 2021;74:3513–22.

21. Bansal N, Vij V, Rastogi M, Wadhawan M, Kumar A. A report on three patients with Echinococcus multilocularis: lessons learned. Indian J Gastroenterol. 2018;37(4):353–8.

22. Bottasso E. Toward the existence of a sympathetic neuroplasticity adaptive mechanism influencing the immune response. A hypothetical view. Part I. Front Endocrinol. 2019;10:632.

23. Liu T, Yang L, Han X, Ding X, Li J, Yang J. Local sympathetic innervations modulate the lung innate immune responses. Sci Adv. 2020;6(20):eaay1497.

24. Huan HB, Wen XD, Chen XJ, Wu L, Wu LL, Zhang L, et al. Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells. Brain Behav Immun. 2017;59:118–34.

25. Conceicao F, Sousa DM, Paredes J, Lamghari M. Sympathetic activity in breast cancer and metastasis: partners in crime. Bone Res. 2021;9(1):9.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.